Additional information
| Trade Name | GLIVEC |
|---|---|
| Generic Name | Imatinib Mesylate |
| Manufacturer | Novartis India Ltd |
| Drug Type | Oncology |
| Indication | Blood Cancer |
| Doasage Form | Tablet |
| Packaging | 1 X 30 Tablets 400mg |
| Strength | 100mg, 400mg |
GLIVEC (Imatinib Mesylate)
₹1.00 – ₹2.00
GLIVEC (Imatinib Mesylate) is classified as a signal transduction inhibitor – protein-Tyrosine kinase inhibitors.
It is used in the treatment of blood cancer (chronic myeloid leukemia CML and Acute lymphocytic leukemia ALL) and (GIST), a type of cancer (sarcoma) of the stomach and bowel and dermatofibrosarcoma protuberans (DFSP), a type of cancer (sarcoma) in which cells in the tissue beneath the skin divide uncontrollably. Glivec is used when the patients are Philadelphia chromosome-positive (Ph+) and who are not eligible for a bone marrow transplant.
Available in Strengths of 100mg & 400mg
